

What is claimed is:

1. A method of enhancing angiogenesis in a mammal, comprising administering an effective amount of hepatocyte growth factor ("HGF") to the mammal.

5

2. The method of claim 1 wherein said HGF has at least 80% sequence identity with a native mammalian HGF.

3. The method of claim 2 wherein said HGF has at least 90% sequence identity with a native mammalian HGF.

10

4. The method of claim 3 wherein said HGF has at least 95% sequence identity with a native mammalian HGF.

15

5. The method of claim 4 wherein said HGF is human HGF.

6. The method of claim 1 wherein said HGF is administered intraarterially.

20

7. The method of claim 6 wherein HGF is additionally administered intravenously.

8. An article of manufacture, comprising:
a container;

25

a label on said container; and

a composition comprising an active agent contained within said container;

30

wherein the composition is effective for enhancing angiogenesis, the label on said container indicates that the composition can be used for enhancing angiogenesis, and the active agent in said composition comprises HGF.

9. The article of manufacture of claim 8 further comprising instructions for administering the HGF to a mammal to enhance angiogenesis.

35

10. A kit, comprising:

a first container, a label on said container, and
a composition comprising an active agent contained within said
container;

5 wherein the composition is effective for enhancing
angiogenesis, the label on said container indicates that the
composition can be used for enhancing angiogenesis, and the
active agent in said composition comprises HGF;

10 a second container comprising a pharmaceutically-
acceptable buffer; and
instructions for using the HGF to enhance angiogenesis.